ASSESSMENT OF THE BRAIN DEPOSIT OF TAU 4R DETECTED BY BRAIN PET WITH 18F-PI2620 IN PROGRESSIVE SUPRANUCLEAR PALSY COMPARED TO CONTROLS WITHOUT NEURODEGENERATIVE TAUOPATHY 4R: A CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503538-37-00

Acronym

CUN-PETNeuroTau

Enrollment

Registered

2023-08-07

Start date

2023-11-13

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive supranuclear palsy

Brief summary

Brain deposit of tau 4R protein by means of the PET-Tau imaging study using the 18F-PI2620 radiotracer

Detailed description

Pattern of glucose metabolism by PET-FDG, Motor (rigidity, bradykinesia, falls, dysarthria, etc.) and non-motor (depression, apathy, cognitive impairment) symptoms

Interventions

DRUG[18F]PI-2620

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Brain deposit of tau 4R protein by means of the PET-Tau imaging study using the 18F-PI2620 radiotracer	—

Secondary

Measure	Time frame
Pattern of glucose metabolism by PET-FDG, Motor (rigidity, bradykinesia, falls, dysarthria, etc.) and non-motor (depression, apathy, cognitive impairment) symptoms	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026